Topline results, to be presented at an upcoming congress, show enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder cancer patients ineligible for cisplatin.
Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's JNJ Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback